國立虎尾科技大學 |

Melatonin, Neuroprotective Agents and Antidepressant Therapy

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Melatonin, Neuroprotective Agents and Antidepressant Therapy/ edited by Francisco López-Muñoz, Venkataramanujam Srinivasan, Domenico de Berardis, Cecilio Álamo, Takahiro A. Kato.
other author:	López-Muñoz, Francisco.
Description:	XXV, 921 p. 178 illus., 113 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Neurology . -
Online resource:	https://doi.org/10.1007/978-81-322-2803-5
ISBN:	9788132228035

Melatonin, Neuroprotective Agents and Antidepressant Therapy
Melatonin, Neuroprotective Agents and Antidepressant Therapy[electronic resource] /edited by Francisco López-Muñoz, Venkataramanujam Srinivasan, Domenico de Berardis, Cecilio Álamo, Takahiro A. Kato. - 1st ed. 2016. - XXV, 921 p. 178 illus., 113 illus. in color.online resource.

History of pineal gland as neuroendocrine organ and discovery of melatonin -- Bibliometric study of scientific research on melatonin during the last 25 years -- Neuroimaging of the pineal gland. Focus on Primary Insomnia -- Melatonin: Basic and clinical aspects -- Melatonin and melatonin receptors in neuroprotection -- Melatonin supplementation in neurodegenerative diseases: Current status -- Therapeutic potential of melatonin in combination with other drugs against neurodegeneration -- Melatonin, a neuroprotective agent: relevance for stress induced neuropsychiatric disorders -- Melatonin, sleep, circadian rhythm and mood disorders -- Melatonin induces antidepressant-like behavior by promotion of hippocampal neurogenesis -- Association between melatonin and neuroimmune diseases -- Melatonin in clinical states of patients with fibromyalgia syndrome -- Melatonin’s beneficial effects in hepatic injury -- Melatonin as a novel therapeutic agent against chemical warfare agents -- New galenic formulations of melatonin -- Melatonergic drug ramelteon in neurotherapeutics -- Melatonergic antidepressant agomelatine and its efficacy in depressive disorders -- Agomelatine, melatonin and depression -- Neuropsychological models of depression -- Chronobiology of mood disorders -- Bipolar disorders and biological rhythm -- Circadian clock genes and mood disorders -- Understanding the biologically adaptive side of mood disorders: a focus on affective temperaments -- Sleep abnormalities as diagnostic tool for major depressive disorder -- Depression: Correlations with thyroid hormones in major depressive disorder -- History of the discovery of antidepressant drugs -- Neurocognitive deficit in bipolar disorders -- Combination strategies in treatment-resistant depression -- Antidepressant drugs in elderly -- Antidepressant efficacy of escitalopram in major depressive disorder -- Antidepressant medications and suicide risk: What was the impact of FDA warning? -- Neurobiology and pharmacological prevention of suicide in mood disorders -- Antidepressants and anticonvulsants as adjuvant analgesics in chronic pain -- Genetic polymorphisms of cytochrome P450 enzymes and antidepressants -- Pharmacogenomics of antidepressant drugs -- Antidepressants modulate microglia beyond the neurotransmitters doctrine of mood disorders -- Brain-derived neurotrophic factor (BDNF) - TrkB signaling in depression: Biomarker and novel therapeutic target -- Targeting opioid receptors for innovative antidepressant therapies: rediscovering the opioid cure -- Prolactin and somatostatin responses to antidepressant therapy -- The role of vasopressin in anxiety and depression -- Ketamine: the glutamatergic antidepressant and its efficacy -- Acetylcholinergic nicotinic receptors as pharmacological targets for cognitive enhancement: emerging evidence from psychosis populations.-The glutamate mGluR5 receptor as a pharmacological target to enhance cognitive function: emerging evidence from psychosis models -- Corticotropin-releasing factor receptors as a potential target in the developments of antidepressant drugs -- Nitric oxide signaling in depression and antidepressant action -- The role of arrestins in the neuroprotective aspects of antidepressant drugs -- Antidepressant drugs and phosphodiesterases -- Effect of methylphenidate and atomoxetine on development of the brain -- S-Adenosyl-L-methionine for major depressive disorder -- The role of antiepileptic drugs in bipolar depression -- Melatonin and other neuroprotective agents target molecular mechanisms of disease in amyotrophic lateral sclerosis.

This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects. .

ISBN: 9788132228035

Standard No.: 10.1007/978-81-322-2803-5doiSubjects--Topical Terms:

1253459
Neurology .

LC Class. No.: RC346-429.2

Dewey Class. No.: 616.8

Melatonin, Neuroprotective Agents and Antidepressant Therapy
LDR:06588nam a22003975i 4500 001 982286
003 DE-He213
005 20200705150702.0
007 cr nn 008mamaa
008 201211s2016 ii | s |||| 0|eng d
020 $a 9788132228035 $9 978-81-322-2803-5
024 7 $a 10.1007/978-81-322-2803-5 $2 doi
035 $a 978-81-322-2803-5
050 4 $a RC346-429.2
072 7 $a MJN $2 bicssc
072 7 $a MED056000 $2 bisacsh
072 7 $a MKJ $2 thema
082 0 4 $a 616.8 $2 23
245 1 0 $a Melatonin, Neuroprotective Agents and Antidepressant Therapy $h [electronic resource] / $c edited by Francisco López-Muñoz, Venkataramanujam Srinivasan, Domenico de Berardis, Cecilio Álamo, Takahiro A. Kato.
250 $a 1st ed. 2016.
264 1 $a New Delhi : $b Springer India : $b Imprint: Springer, $c 2016.
300 $a XXV, 921 p. 178 illus., 113 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a History of pineal gland as neuroendocrine organ and discovery of melatonin -- Bibliometric study of scientific research on melatonin during the last 25 years -- Neuroimaging of the pineal gland. Focus on Primary Insomnia -- Melatonin: Basic and clinical aspects -- Melatonin and melatonin receptors in neuroprotection -- Melatonin supplementation in neurodegenerative diseases: Current status -- Therapeutic potential of melatonin in combination with other drugs against neurodegeneration -- Melatonin, a neuroprotective agent: relevance for stress induced neuropsychiatric disorders -- Melatonin, sleep, circadian rhythm and mood disorders -- Melatonin induces antidepressant-like behavior by promotion of hippocampal neurogenesis -- Association between melatonin and neuroimmune diseases -- Melatonin in clinical states of patients with fibromyalgia syndrome -- Melatonin’s beneficial effects in hepatic injury -- Melatonin as a novel therapeutic agent against chemical warfare agents -- New galenic formulations of melatonin -- Melatonergic drug ramelteon in neurotherapeutics -- Melatonergic antidepressant agomelatine and its efficacy in depressive disorders -- Agomelatine, melatonin and depression -- Neuropsychological models of depression -- Chronobiology of mood disorders -- Bipolar disorders and biological rhythm -- Circadian clock genes and mood disorders -- Understanding the biologically adaptive side of mood disorders: a focus on affective temperaments -- Sleep abnormalities as diagnostic tool for major depressive disorder -- Depression: Correlations with thyroid hormones in major depressive disorder -- History of the discovery of antidepressant drugs -- Neurocognitive deficit in bipolar disorders -- Combination strategies in treatment-resistant depression -- Antidepressant drugs in elderly -- Antidepressant efficacy of escitalopram in major depressive disorder -- Antidepressant medications and suicide risk: What was the impact of FDA warning? -- Neurobiology and pharmacological prevention of suicide in mood disorders -- Antidepressants and anticonvulsants as adjuvant analgesics in chronic pain -- Genetic polymorphisms of cytochrome P450 enzymes and antidepressants -- Pharmacogenomics of antidepressant drugs -- Antidepressants modulate microglia beyond the neurotransmitters doctrine of mood disorders -- Brain-derived neurotrophic factor (BDNF) - TrkB signaling in depression: Biomarker and novel therapeutic target -- Targeting opioid receptors for innovative antidepressant therapies: rediscovering the opioid cure -- Prolactin and somatostatin responses to antidepressant therapy -- The role of vasopressin in anxiety and depression -- Ketamine: the glutamatergic antidepressant and its efficacy -- Acetylcholinergic nicotinic receptors as pharmacological targets for cognitive enhancement: emerging evidence from psychosis populations.-The glutamate mGluR5 receptor as a pharmacological target to enhance cognitive function: emerging evidence from psychosis models -- Corticotropin-releasing factor receptors as a potential target in the developments of antidepressant drugs -- Nitric oxide signaling in depression and antidepressant action -- The role of arrestins in the neuroprotective aspects of antidepressant drugs -- Antidepressant drugs and phosphodiesterases -- Effect of methylphenidate and atomoxetine on development of the brain -- S-Adenosyl-L-methionine for major depressive disorder -- The role of antiepileptic drugs in bipolar depression -- Melatonin and other neuroprotective agents target molecular mechanisms of disease in amyotrophic lateral sclerosis.
520 $a This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects. .
650 0 $a Neurology . $3 1253459
650 0 $a Psychopharmacology. $3 644799
650 0 $a Internal medicine. $3 644638
650 1 4 $a Neurology. $3 593894
650 2 4 $a Internal Medicine. $3 668583
700 1 $a López-Muñoz, Francisco. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1274423
700 1 $a Srinivasan, Venkataramanujam. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1274424
700 1 $a de Berardis, Domenico. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1274425
700 1 $a Álamo, Cecilio. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1274426
700 1 $a Kato, Takahiro A. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1274427
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9788132228011
776 0 8 $i Printed edition: $z 9788132228028
776 0 8 $i Printed edition: $z 9788132238423
856 4 0 $u https://doi.org/10.1007/978-81-322-2803-5
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)